{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:40:03Z","timestamp":1770507603562,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00228-015-1847-6","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T04:40:52Z","timestamp":1430714452000},"page":"707-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment"],"prefix":"10.1007","volume":"71","author":[{"given":"Philip D.","family":"Worboys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shekman L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Barriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"issue":"7","key":"1847_CR1","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","volume":"52","author":"KM Krause","year":"2008","unstructured":"Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM (2008) In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 52(7):2647\u20132652","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1847_CR2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","volume":"49","author":"DL Higgins","year":"2005","unstructured":"Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49(3):1127\u20131134","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1847_CR3","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","volume":"53","author":"CS Lunde","year":"2009","unstructured":"Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM (2009) Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 53(8):3375\u20133383","journal-title":"Antimicrob Agents Chemother"},{"key":"1847_CR4","unstructured":"Health Canada (2010) VIBATIV\u00ae. Available at http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/sbd-smd\/phase1-decision\/drugmed\/sbd_smd_2010_vibativ_107792-eng.pdf . Accessed 19 March 2015"},{"key":"1847_CR5","unstructured":"VIBATIV\u00ae [package insert] (2009). South San Francisco, CA: Theravance, Inc. Available at: http:\/\/www.vibativ.com . Accessed 19 March 2015"},{"key":"1847_CR6","unstructured":"Clinigen Healthcare Ltd (2014) VIBATIV summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001240\/WC500115364.pdf . Accessed 19 March 2015"},{"issue":"1","key":"1847_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","volume":"49","author":"JP Shaw","year":"2005","unstructured":"Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S (2005) Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 49(1):195\u2013201","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1847_CR8","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkn273","volume":"62","author":"SL Wong","year":"2008","unstructured":"Wong SL, Barriere SL, Kitt MM, Goldberg MR (2008) Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 62(4):780\u2013783","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1847_CR9","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.01750-09","volume":"54","author":"JP Shaw","year":"2010","unstructured":"Shaw JP, Cheong J, Goldberg MR, Kitt MM (2010) Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother 54(8):3365\u20133371","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1847_CR10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.30.8.806","volume":"30","author":"MR Goldberg","year":"2010","unstructured":"Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL (2010) Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 30(8):806\u2013811","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1847_CR11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0091270009337133","volume":"49","author":"SL Wong","year":"2009","unstructured":"Wong SL, Sorgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL (2009) Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin\/tazobactam in healthy participants. J Clin Pharmacol 49(7):816\u2013823","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1847_CR12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"issue":"6","key":"1847_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461\u2013470","journal-title":"Ann Intern Med"},{"key":"1847_CR14","unstructured":"Tukey JW (1977) Exploratory data analysis. Addison-Wesley"},{"issue":"8","key":"1847_CR15","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/AAC.48.8.3151-3153.2004","volume":"48","author":"JF Mohr","year":"2004","unstructured":"Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L (2004) Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 48(8):3151\u20133153","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1847-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1847-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1847-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T19:12:52Z","timestamp":1551208372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1847-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1847-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]}}}